ORYZON receives approval to start ALICE: a Phase IIa clinical trial in AML with Iadademstat (ORY-1001)
2018-09-10 · Oryzon Genomics S.A. · original oryzon.com ↗
10 September 2018 MADRID, SPAIN and CAMBRIDGE MA. • The study will be done in elderly Acute Myeloid Leukemia (AML) patients not eligible for intensive chemotherapy • It is the first Phase II study of Iadademstat (ORY-1001) in combination therapy Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today that it has received approval of a Clinical Trial Application (CTA), the European IND equivalent, from the Spanish Drug Agency (AEMPS) to conduct a Phase IIa clinical study with Iadademstat (ORY-1001) in elderly Acute Myeloid Leukemia (AML) patients not eligible for intensive chemotherapy. Click here to see the full Press Release
The release as fetched from its publisher. oryzon.com ↗